title: A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.
abstract: Lamivudine resistance has been described in subjects with chronic hepatitis B infections, associated with mutations in the viral polymerase gene. The objective of this study was to estimate the emergence rate of lamivudine-resistant viral strains and their consequences over a 2-year period. We evaluated 283 lamivudine-naïve subjects with chronic hepatitis B. Clinical and virological features were assessed at inclusion and every 6 months thereafter. Viral DNA was characterized using polymerase chain reaction (PCR)-based sequencing. Potential risk factors for the emergence of lamivudine resistance mutations were assessed using logistic regression analysis. The annualized incidence rate for viral polymerase mutations was 22%. The only independent risk factor identified was high viral load, at inclusion. Detectable viral DNA and elevated transaminases were more frequent in subjects harbouring mutant viral strains, and these underwent a lower rate of hepatitis B e seroconversion. All subjects responded favourably to treatment, with no difference in symptoms between the two groups. This prospective cohort study identified lamivudine-resistant mutations emerging in 22% of subjects, yearly, which were apparently not associated with clinical aggravation over the study period.
authors.affiliation: INSERM U271, Lyon, France.
authors.forename: F
authors.initials: F
authors.lastname: Zoulim
authors.forename: T
authors.initials: T
authors.lastname: Poynard
authors.forename: F
authors.initials: F
authors.lastname: Degos
authors.forename: A
authors.initials: A
authors.lastname: Slama
authors.forename: A
authors.initials: A
authors.lastname: El Hasnaoui
authors.forename: P
authors.initials: P
authors.lastname: Blin
authors.forename: F
authors.initials: F
authors.lastname: Mercier
authors.forename: P
authors.initials: P
authors.lastname: Deny
authors.forename: P
authors.initials: P
authors.lastname: Landais
authors.forename: P
authors.initials: P
authors.lastname: Parvaz
authors.forename: C
authors.initials: C
authors.lastname: Trepo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005602:France; D006510:Hepatitis B Antibodies / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D017422:Sequence Analysis, DNA; D018709:Statistics, Nonparametric
chemical_list: D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine